DEFA14A: Vaxart Adjourns Special Stockholder Meeting to Sept 19

Vaxart, Inc. has adjourned its 2025 special meeting of stockholders to September 19, 2025, to allow more time for consideration of recent board and governance changes, and potential future disclosures.

Summary

• Vaxart, Inc. (OTCQX: VXRT) announced the adjournment of its 2025 special meeting of stockholders.
• The reconvened Special Meeting is scheduled for Friday, September 19, 2025, at 8:30 a.m. Pacific Time.
• The adjournment provides stockholders additional time to consider and vote on all proposals, including a reverse stock split, in light of recent Board composition changes, additional governance changes under consideration, and potential future company disclosures.
• Management emphasizes that a Nasdaq listing is integral to advancing the company's science and maximizing stockholder value.
• Stockholders of record on July 29, 2025, who have not yet voted, are encouraged to do so by 11:59 p.m. Eastern Time on September 18, 2025.
• Proxies previously submitted will be voted unless properly revoked, and stockholders who have already voted need not take further action but can change their vote.

Sentiment

Score: 5

Explanation: The adjournment itself is neutral to slightly negative as it indicates unresolved issues, but the stated reasons (board changes, governance considerations, potential disclosures) could be interpreted as management being proactive. The pursuit of a Nasdaq listing is a positive strategic goal.

Positives

• Management is actively engaging with stockholders to discuss important issues and gather feedback, indicating a commitment to investor relations.
• The company is pursuing a Nasdaq listing, which management believes is integral to advancing its science and maximizing stockholder value, potentially enhancing market visibility and liquidity.
• The Board is considering additional governance changes, which could lead to improved corporate oversight and investor confidence.

Negatives

• The necessity of adjourning the special meeting suggests a lack of sufficient stockholder consensus or preparedness for key proposals, such as the reverse stock split.
• The delay in voting on the reverse stock split could prolong the process of achieving a Nasdaq listing, if that is the primary purpose of the split, potentially extending the period of uncertainty.
• The mention of 'potential other disclosures' creates uncertainty regarding future company announcements, which could impact investor sentiment.

Risks

• The company faces risks related to its ability to stay listed on Nasdaq or regain and maintain compliance with the Bid Price Rule.
• Uncertainty exists regarding the outcome of the special meeting proposals, including the reverse stock split, which could affect the company's strategic direction.
• General business risks and uncertainties are described in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Management believes that achieving a Nasdaq listing is integral to advancing the company's scientific endeavors and maximizing stockholder value. Vaxart, as a clinical-stage biotechnology company, continues to develop a range of oral recombinant vaccines for indications such as coronavirus, norovirus, influenza, and human papillomavirus (HPV). The company's future performance and ability to maintain a Nasdaq listing are subject to various known and unknown risks and uncertainties.

Management Comments

• "We continue to believe that a listing on Nasdaq is integral to advancing our science and maximizing stockholder value." Steven Lo, Chief Executive Officer.
• "We look forward to engaging with our stockholders over the next two weeks to discuss this important issue and listen to their feedback." Steven Lo, Chief Executive Officer.

Industry Context

The biotechnology industry, particularly for clinical-stage companies like Vaxart, often relies on capital markets for funding and growth. A Nasdaq listing is generally perceived as a significant step for such companies, offering increased visibility, liquidity, and access to institutional investors compared to the OTCQX market. The development of oral vaccines represents an innovative segment within the pharmaceutical industry, potentially offering advantages in logistics, administration, and patient compliance.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Provided with additional time to consider and vote on important proposals, including a reverse stock split crucial for a potential Nasdaq listing. They face uncertainty regarding the outcome of the vote and future disclosures.
• **Management/Board**: Actively engaging with stockholders and considering governance changes to address current challenges and strategic objectives.
• **Employees**: No direct impact mentioned, but a successful Nasdaq listing could improve the company's profile and potentially enhance the value of employee stock options.

Next Steps

• Vaxart will continue to solicit votes from its stockholders for all proposals set forth in the Proxy Statement.
• Stockholders are encouraged to vote by 11:59 p.m. Eastern Time on September 18, 2025.
• The reconvened Special Meeting will be held virtually on September 19, 2025, at 8:30 a.m. Pacific Time.
• The Board of Directors is considering and may announce additional governance changes.
• The Company may provide potential other disclosures in the future.

Key Dates

Recommendation

The adjournment introduces uncertainty regarding key strategic initiatives like the reverse stock split and Nasdaq listing. While management's stated reasons (board changes, governance review, potential disclosures) could be positive in the long run, the immediate impact is a delay. Investors should hold to await the outcome of the reconvened meeting and further disclosures before making significant investment decisions. The pursuit of a Nasdaq listing is a positive long-term goal, but the path to it is currently unclear.

Keywords

Vaxart, VXRT, Special Meeting, Stockholders, Proxy Statement, Reverse Stock Split, Nasdaq Listing, Biotechnology, Oral Vaccines, Clinical Stage, Corporate Governance, SEC Filing